Teva: No Reason To "Panic" When It Comes To Ajovy Access
Discussions with payers for market access for the migraine drug will continue through November and into December. The level of rebating in the category will be around 25%, management forecast.
You may also be interested in...
CGRP inhibitors were a hot topic during third quarter earnings calls, with Amgen and Teva talking about reimbursement progress, while Lilly marked progress for its add-on treatment, Allergan calmed fears about Botox's migraine sales, and Alder said its intravenous drug is on track.
Agreement between Amgen/Novartis and Eli Lilly with Express Scripts on new migraine drugs could spur more demand by payers for simple, value-based outcomes deals.
The US FDA approved Teva's fremanezumab dosed monthly and quarterly versus Amgen's monthly Aimovig, and will launch at the same price. However, it's packaged as a pre-filled syringe instead of an autoinjector, has a higher rate of injection site reactions and it may launch alongside Lilly's Emgality.